The Federal Trade Commission held a workshop to explore competition issues involving biologic medicines and follow-on biologics. As described in the Federal Register Notice, the workshop focused on a few key issues, inter alia:
- The potential impact of state regulations affecting competition.
- How regulations, if necessary, might be structured to facilitate competition while still protecting patient health and safety.
- How naming may affect competition.
- The experience of other countries with follow-on biologic competition.
Webcast and Transcript
The workshop webcast videos are available for viewing (under Video, below). Viewers may want to review the panelist slide presentations (under Event Speakers, below) as they watch the videos. A transcript of the workshop is available as well (under Transcript, below).